- Record Subsea Technologies and Surface Technologies operating profit - Strong Subsea Technologies orders of $1.1 billion - Increased full year diluted earnings per share guidance: $2.75 to $2.85
HOUSTON , Oct.
CN reports Q3-2014 net income of C$853 million, up 21 per cent from year-earlier net income of C$705 million Canada NewsWire
Financial outlook and 2014 key assumptions CN maintains the 2014 financial outlook it issued on July 21, 2014 .
No evidence of negative effects on bone mineral density Treatment benefit is sustained with 79.3% of subjects exhibiting normal morning testosterone after 12 months of treatment (LOCF 71.4%) No new safety signals detected with long-term treatment
THE WOODLANDS, Texas, Oct.
Interactive Brokers Group, Inc. (NASDAQ GS:IBKR) an automated global
electronic broker and market maker, today reported diluted loss per
share on a comprehensive basis of $0.13 for the quarter ended September
30, 2014, compared to diluted earnings per share on a comprehensive
basis of $0.39 for the same period in 2013.
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and
joint restoration products for hip, knee, shoulder and spine, announced
today revenue of $57.9 million for the third quarter of 2014, a 4%
increase over $55.7 million in the third quarter of 2013.
NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science
tools for translational research and molecular diagnostic products,
today announced that the Journal of Clinical Oncology published
an analysis of data in over 2,100 patients showing that the
risk-of-recurrence (ROR) score generated by the PAM50-based Prosigna™
Breast Cancer Assay predicts the risk of late distant recurrence, after
five years of endocrine therapy, in postmenopausal women with Hormone
Receptor-Positive (HR+) early-stage breast cancer.
Sign-up for NanoString Announces Publication in the Journal of Clinical Oncology Showing the Prosigna Assay Identifies Women With a Low Risk of Late Distant Recurrence of Breast Cancer investment picks
Executive Snapshot: Continued strong financial results:
Year-to-Date 2014 compared to the same period in 2013:
Net income up 14.9%
Diluted EPS up 14.2%
Return on average assets (ROA) rose 9 basis points to 0.98%
Return on average equity (ROE) rose 90 basis points to 11.84%
Improvement in the efficiency ratio from 52.99% in 2013 to 52.35% in 2014
Third quarter 2014 compared to third quarter 2013:
Net income up 4.5%
Diluted EPS up 3.7%
Return on average assets (ROA) up an additional basis point to 0.92% Asset quality improvement:
Virtually every measure of asset quality improved during the third quarter
Nonperforming assets (NPAs) fell $8.0 million or 16% to $43.6 million at September 30, 2014 compared to $51.6 million at September 30, 2013
NPAs to total assets improved from 1.16% to 0.95% over
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.